Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
IRAK-4 inhibitor
IRAK inhibitor 1 is a potent IRAK-4 inhibitor with IC50 of 216 nM, is poorly active against JNK-1 and JNK-2 with IC50 of 3.801 μM, and >10 μM, respectively. -
interleukin-1 receptor associated kinase inhibitor
IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor . -
IRAK4 inhibitor
IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor. -
IRAK inhibitor
IRAK-IN-6, also known as IRAK inhibitor 6, is an interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor. IRAK-4 is reported to be essential for the activation of the intracellular signalling cascades including NF-kB and MAPK pathways, which are critical for the production of inflammatory cytokines. -
IRAK4 inhibitor
AS-2444697 is a potent and selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with IC50 value of 21 nM. -
IRAK4 inhibitor
PF-06650833 is an inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4). -
IRAK4 inhibitor
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM. -
IRAK4 inhibitor
IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM. -
IRAK4/FLT3 inhibitor
Emavusertib, also known as CA-4948 is a potent IRAK4/FLT3 inhibitor with anti-tumor activity. CA-4948 demonstrated good cellular activity in ABC DLBCL and AML cell lines. CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation. -
TAK1 inhibitor
HS-276 is an orally bioavailable, potent, and highly selective inhibitor of transforming growth factor-β–activated kinase 1 (TAK1), with a Kᵢ of 2.5 nM. It exhibits strong inhibition of TAK1 and moderate activity against a panel of other kinases, including CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with respective IC₅₀ values ranging from 8.25 to 5585 nM. HS-276 is a valuable tool for investigating TAK1-mediated signaling pathways and holds therapeutic potential for inflammatory conditions such as rheumatoid arthritis (RA). -
IRAK4 Inhibitor
IRAK4-IN-33 is a selective and potent inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 of 0.36 nM. This compound effectively disrupts the pro-inflammatory signaling pathway associated with IRAK4, leading to decreased release of inflammatory cytokines such as TNFα and IFNα. IRAK4-IN-33 demonstrates minimal inhibition of the hERG channel, with an IC50 greater than 30 μM, making it a valuable tool for studying inflammation and immunological disorders, including rheumatoid arthritis. -
IRAK4 Inhibitor
GLPG4471 is a selective inhibitor of IRAK4, demonstrating an IC50 of 1.7 nM. It exhibits potent inhibition of cytokine secretion, including TNFα and IFNα, in both cellular and whole blood assays. Notably, GLPG4471 shows significant therapeutic activity in a mouse model of collagen-induced arthritis, making it a valuable tool for researching inflammatory conditions such as arthritis. -
IRAK4 Inhibitor
Emavusertib hydrochloride is an orally active inhibitor targeting IRAK4, with an IC50 of 57 nM, and FLT3. This compound effectively inhibits NF-κB and MyD88 signaling pathways, resulting in decreased production of pro-inflammatory cytokines such as IL-6 and IL-10. Its anti-inflammatory and anti-proliferative properties make it a valuable tool for cancer research, as it promotes apoptosis in cancer cells and demonstrates antitumor efficacy in mouse model studies. -
IRAK Inhibitor
KME-2780 is an orally active inhibitor targeting IRAK1 and IRAK4, exhibiting IC50 values of 19 nM and 0.5 nM, respectively. It plays a crucial role in the modulation of innate immune signaling pathways, making it a valuable tool for investigating dysregulation associated with hematologic malignancies and related disorders. Researchers can utilize KME-2780 to explore the therapeutic potential of IRAK inhibition in various immunological contexts. -
IRAK4/IRAK1 Inhibitor
IRAK4 modulator-2 is a selective inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and IRAK1, exhibiting IC50 values of 0.005 μM and 0.97 μM, respectively. This compound effectively disrupts IRAK-mediated signaling pathways, including JAK-STAT and NF-κB pathways, leading to a reduction in pro-inflammatory cytokine production, such as IL-1 and TNF. IRAK4 modulator-2 demonstrates potential for use in research focusing on autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. -
IRAK1 Kinase Inhibitor
IRAK1/4/pan-FLT3 Kinase-IN-1 is a selective inhibitor targeting IRAK1, IRAK4, and FLT3 kinases, demonstrating IC50 values of 5 nM for IRAK1, 0.6 nM for IRAK4, and less than 0.5 nM for FLT3. This compound exhibits strong pharmacokinetic properties, indicating its potential for therapeutic application in acute myeloid leukemia research. Its efficacy in promoting survival suggests it may serve as a valuable tool for exploring novel treatment strategies in hematological malignancies. -
FLT3/IRAK4 Inhibitor
Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor that demonstrates significant antitumor activity. It is particularly relevant for research involving myeloid leukemia, where it may offer insights into therapeutic strategies targeting these pathways. Its unique mechanism of action makes it a valuable tool for investigating the roles of FLT3 and IRAK4 in cancer biology. -
FLT3/IRAK1/4 Inhibitor
NCGC1481 is a potent inhibitor of FLT3, IRAK1, and IRAK4, displaying IC50 values of <0.5 nM, 22.6 nM, and 0.8 nM, respectively. This compound effectively mitigates the adaptive resistance of leukemia cells to FLT3 inhibitors, demonstrating significant antileukemic activity. NCGC1481 is suitable for research focused on leukemia treatment and the modulation of key signaling pathways involved in cancer cell survival and proliferation. -
IRAK4 Inhibitor
IRAK4-IN-27 is a selective inhibitor of IRAK4, exhibiting an IC50 of 8.7 nM. This compound effectively inhibits cell growth and induces apoptosis in MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell lines. IRAK4-IN-27 is an important tool for studying the mechanisms underlying DLBCL and developing potential therapeutic strategies. -
TrkB Inhibitor
PC-046 is a potent multitarget inhibitor of tyrosine receptor kinase B (TrkB), IRAK-4, and Pim-1, with IC50 values of 13.4 μM, 15.4 μM, and 19.1 μM, respectively. This compound demonstrates significant cytotoxicity against BxPC3 pancreatic cancer cells, with an IC50 range of 7.5-130 nM. PC-046 effectively induces apoptosis and disrupts the cell cycle at the G2/M phase in these cells. Additionally, it showcases promising antitumor efficacy and favorable pharmacokinetic properties in murine models, making it a valuable tool for cancer research. -
IRAK4 Inhibitor
Emavusertib phosphate is a potent inhibitor of IRAK4, exhibiting an IC50 of 57 nM. This compound effectively disrupts NF-κB and MyD88 signaling pathways, leading to a significant reduction in pro-inflammatory cytokines such as IL-6 and IL-10. Emavusertib phosphate demonstrates both anti-inflammatory and anti-proliferative effects on cancer cells, promoting apoptosis and showcasing antitumor activity in preclinical mouse models. Its applications extend to investigating inflammatory diseases and cancer therapies. -
IRAK4 Inhibitor
Emavusertib maleate is a potent inhibitor of IRAK4, demonstrating an IC50 of 57 nM, and FLT3. This orally bioavailable compound inhibits NF-κB and MyD88 signaling pathways, effectively reducing the production of pro-inflammatory cytokines such as IL-6 and IL-10. Its anti-inflammatory and anti-proliferative properties make it a valuable tool for cancer research, promoting apoptosis in cancer cells and demonstrating antitumor activity in preclinical mouse models. -
IRAK4 Inhibitor
Emavusertib tosylate is a potent inhibitor of IRAK4, displaying an IC50 of 57 nM. By targeting IRAK4 and FLT3, it effectively disrupts NF-κB and MyD88 signaling pathways, resulting in the reduction of pro-inflammatory cytokines such as IL-6 and IL-10. This compound demonstrates significant anti-inflammatory and anti-proliferative properties against cancer cells, promoting apoptotic mechanisms. Additionally, Emavusertib tosylate has shown noteworthy antitumor activity in preclinical mouse models, making it a valuable reagent for cancer research and inflammation studies. -
IRAK4 Inhibitor
Emavusertib mesylate is a potent inhibitor of IRAK4, demonstrating an IC50 of 57 nM. This orally active compound effectively disrupts the NF-κB and MyD88 signaling pathways, leading to a reduction in pro-inflammatory cytokines such as IL-6 and IL-10. Emavusertib mesylate displays anti-inflammatory and anti-proliferative properties against cancer cells, promoting apoptosis. Additionally, it has shown significant antitumor activity in mouse models, making it valuable for cancer research and therapeutic studies targeting inflammatory pathways. -
IRAK4 Inhibitor
BMS-986126 is a potent and selective inhibitor of IRAK4, with an IC50 value of 5.3 nM. It effectively disrupts MyD88-dependent signaling pathways, thereby attenuating inflammatory responses associated with autoimmune conditions. In preclinical studies, BMS-986126 has demonstrated significant efficacy in murine models of lupus, including MRL/lpr and NZB/NZW strains. This compound is valuable for research applications related to systemic lupus erythematosus (SLE) and other autoimmune diseases. -
c-Met Inhibitor
Tepotinib hydrochloride is a highly selective, reversible, ATP-competitive inhibitor of c-Met, exhibiting an IC50 of 3 nM and over 200-fold selectivity for c-Met compared to other kinases such as IRAK4, TrkA, Axl, IRAK1, and Mer. This compound effectively inhibits c-Met phosphorylation and promotes autophagy. Tepotinib hydrochloride demonstrates significant antitumor activity and is applicable in cancer research targeting c-Met-driven pathways. -
IRAK4 Inhibitor
UR241-2 is a selective inhibitor of IRAK4, targeting the IL-1–induced IRAK1/4 signaling pathway. It effectively suppresses NF-κB activation and the phosphorylation of p65 and p38, contributing to a reduction in leukemia stem cell clonogenicity. UR241-2 also serves as a valuable ligand for developing PROTAC degraders targeting IRAK4, making it a suitable tool for research in acute myeloid leukemia. -
IRAK4 Inhibitor
Zabedosertib is a selective inhibitor of IRAK4, a protein kinase integral to the signaling pathways of innate immune responses triggered by Toll-like receptors. With an IC50 of 3.55 nM, Zabedosertib demonstrates significant immunomodulatory effects, specifically exhibiting anti-inflammatory activity against IL-1β, lipopolysaccharide (LPS), and Imiquimod-induced inflammation. This compound is suitable for research applications focused on exploring innate immunity and inflammation modulation. -
IRAK1 Inhibitor
JH-X-119-01 is a selective inhibitor of interleukin-1 receptor-associated kinases 1 (IRAK1) that demonstrates significant potential in immunological research. With an IC50 of 9 nM, JH-X-119-01 effectively inhibits IRAK1 activity without affecting IRAK4 at concentrations up to 10 μM. This compound has been shown to mitigate LPS-induced sepsis in animal models, making it a valuable tool for studies focused on inflammation and sepsis-related pathways. -
IRAK-4 Inhibitor
Edecesertib is a selective and potent inhibitor of the interleukin-1 receptor-associated kinase 4 (IRAK-4). It exhibits significant anti-inflammatory activity, making it valuable in the study of inflammatory diseases. Edecesertib is applicable in research focused on rheumatoid arthritis (RA) and lupus erythematosus (LE), contributing to the understanding of therapeutic targets in these conditions. -
IRAK1 Inhibitor
JH-X-119-01 hydrochloride is a selective inhibitor of interleukin-1 receptor-associated kinase 1 (IRAK1), a key player in inflammatory signaling pathways. This compound demonstrates significant potential in reducing LPS-induced sepsis in murine models, indicating its utility in studying inflammatory disorders. Researchers can leverage JH-X-119-01 hydrochloride to explore IRAK1's role in immune responses and develop targeted therapies for sepsis and related conditions. -
IRAK4 Inhibitor
IRAK4-IN-21 is a potent and selective inhibitor of IRAK4, exhibiting IC50 values of 5 nM for IRAK4 and 56 nM for TAK1. This orally active compound effectively inhibits interleukin-23 (IL-23) production with an IC50 of 0.17 μM. IRAK4-IN-21 is valuable for research applications in autoimmune diseases, particularly in the context of plaque psoriasis and psoriatic arthritis. -
IRAK Inhibitor
IRAK4-IN-6 is a selective inhibitor of IRAK4, demonstrating an IC50 of 4 nM. It effectively targets the MyD88 L265P mutant variant associated with diffuse large B cell lymphoma, making it a valuable tool for research in oncology and immune signaling pathways. Its oral efficacy supports in vivo studies, facilitating investigations into IRAK4's role in tumorigenesis and potential therapeutic interventions. -
IRAK4 Inhibitor
IRAK4-IN-22 is a selective IRAK4 inhibitor with potent activity, exhibiting IC50 values of 3 nM for IRAK4 and 17 nM for TAK1. This compound effectively inhibits IL-23 production with an IC50 of 0.10 µM, making it a valuable tool for research into autoimmune conditions such as plaque psoriasis and psoriatic arthritis. Its oral bioavailability enhances its suitability for in vivo studies, facilitating investigations into the therapeutic potential of targeting IRAK4 in inflammatory diseases. -
IRAK4 Inhibitor
BIO-7488 is a selective IRAK4 inhibitor with a potent IC50 of 0.5 nM, designed to cross the blood-brain barrier effectively. This compound inhibits the production of pro-inflammatory cytokines, including IL-1β, TNFα, and IL-6, displaying significant anti-inflammatory properties in both LPS-induced and distal hypoxic-middle cerebral artery occlusion ischemic stroke models. BIO-7488 is a valuable reagent for researching neuroinflammatory disorders, particularly in the context of ischemic stroke. -
IRAK4 Inhibitor
IRAK4-IN-20 is a potent inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), showcasing an IC50 of 3.55 nM. This compound is indicated for research into inflammatory conditions, particularly acute respiratory distress syndrome (ARDS). Its mechanism of action makes it a valuable tool for studying IRAK4's role in immune signaling pathways and related therapeutic interventions. -
IRAK4 Inhibitor
GLPG2534 is a selective inhibitor of IRAK4, exhibiting IC50 values of 6.4 nM and 3.5 nM for human and mouse IRAK4 respectively. This compound effectively modulates inflammatory signaling pathways involved in immune responses. GLPG2534 is suitable for research aimed at understanding and developing treatments for inflammatory skin diseases. -
IRAK4 Inhibitor
IRAK4-IN-14 is a potent, selective inhibitor of IRAK4, demonstrating an IC50 of 0.003 µM. This orally active compound exhibits favorable pharmacokinetic properties in both rat and mouse models. IRAK4-IN-14 has shown synergy in vitro against MyD88/CD79 double mutant ABC-DLBCL when used in combination with Acalabrutinib, making it a valuable tool for research in oncology and inflammation pathways. -
IRAK4 Inhibitor
PF-06426779 is a potent and selective inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), displaying an IC50 of 0.3 nM. This compound effectively modulates inflammatory signaling pathways and is useful in the study of diseases related to dysregulated immune responses. Researchers can leverage PF-06426779 in experimental settings exploring the roles of IRAK4 in cellular processes and potential therapeutic interventions in inflammation-driven disorders. -
IRAK-4 Inhibitor
IRAK-4 protein kinase inhibitor 2 selectively targets interleukin-1 receptor-associated kinase-4 (IRAK-4) with an IC50 of 4 μM. This inhibitor is instrumental in studying inflammatory and immune-related diseases, offering valuable insights into the mechanisms underlying these conditions. Its effective application in research may lead to better understanding and potential therapeutic developments in immune responses. -
IRAK4 Inhibitor
HS271 is a selective inhibitor of IRAK4, demonstrating potent activity with an IC50 of 7.2 μM. This compound exhibits superior enzymatic and cellular efficacy, making it suitable for studies investigating IRAK4-mediated signaling pathways. HS271’s excellent pharmacokinetic properties further enhance its utility in various biological research applications focused on inflammatory processes and immune response modulation. -
IRAK4 Inhibitor
GNE-2256 is a potent inhibitor of IRAK4 (Interleukin 1 receptor associated kinase 4) with a Ki of 1.4 nM, demonstrating high selectivity for this target. It effectively reduces IL-6 production with an IC50 of 190 nM, making it a valuable tool for investigating inflammatory responses and signaling pathways. GNE-2256 is suitable for studies involving autoimmune diseases and other conditions related to aberrant IL-6 signaling. -
IRAK Inhibitor
IRAK inhibitor 4 (trans) is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). This compound has demonstrated significant efficacy in blocking IRAK4 activation, thereby modulating the downstream signaling pathways involved in inflammatory responses. It is widely used in research applications focusing on inflammatory disorders and signaling pathways associated with innate immunity. -
IRAK4 Inhibitor
IRAK4-IN-8 is a potent inhibitor of IRAK4, an essential kinase in the interleukin-1 receptor (IL-1R) and Toll-like receptor (TLR) signaling pathways. By selectively inhibiting IRAK4, it modulates downstream inflammatory responses, making it a valuable tool for studying immune pathways. Its primary applications include research on autoimmune disorders, cancer immunotherapy, and the development of novel anti-inflammatory drugs. -
IRAK4 Inhibitor
IRAK4-IN-18 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 value of 15 nM. This compound is effective in inhibiting lipopolysaccharide (LPS)-induced interleukin-23 (IL-23) production in THP-1 and dendritic cells, demonstrating its potential to modulate inflammatory responses. IRAK4-IN-18 is applicable for research into arthritis and related inflammatory diseases.
